
    
      This is a Phase 2, multi-center, Investigator-masked, randomized, parallel-group study to
      evaluate the tolerability, efficacy and safety of VOS versus Restasis® over a 28-day
      treatment period in subjects with mild to moderate DED. Approximately 90 subjects will be
      randomized to either VOS or Restasis® at approximately 7 centers located in the US
    
  